AR068822A1 - Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso - Google Patents
Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, procesoInfo
- Publication number
- AR068822A1 AR068822A1 ARP080104055A ARP080104055A AR068822A1 AR 068822 A1 AR068822 A1 AR 068822A1 AR P080104055 A ARP080104055 A AR P080104055A AR P080104055 A ARP080104055 A AR P080104055A AR 068822 A1 AR068822 A1 AR 068822A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- pharmaceutical
- propenamide
- indol
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- -1 2-methyl-1H-indol-3-yl Chemical group 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 abstract 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 abstract 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 125000000185 sucrose group Chemical group 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica, la cual comprende: (a) N-hidroxi-3-[4-[[[(2-(2-metil-1H-indol-3-il)-etil]-amino]-metil]-fenil]-2E-2-propenamida, o una sal farmacéuticamente aceptable de la misma; (b) un regulador del pH o un componente regulador del pH; (c) un agente de volumen. Reivindicacion 2: La composicion de la reivindicacion 1, la cual comprende además un quelante/antioxidante. Reivindicacion 3: La composicion de la reivindicacion 1, en donde el agente de volumen mencionado se selecciona a partir de sacarosa, trehalosa, dextrano, y HPbCD. Reivindicacion 4: La composicion de la reivindicacion 2, en donde el quelante/antioxidante mencionado es EDTA disodica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97383007P | 2007-09-20 | 2007-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068822A1 true AR068822A1 (es) | 2009-12-09 |
Family
ID=40005335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104055A AR068822A1 (es) | 2007-09-20 | 2008-09-18 | Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20100331387A1 (es) |
| EP (1) | EP2205222A1 (es) |
| JP (1) | JP2010540445A (es) |
| KR (1) | KR20100059887A (es) |
| CN (1) | CN101801345A (es) |
| AR (1) | AR068822A1 (es) |
| AU (1) | AU2008302273A1 (es) |
| BR (1) | BRPI0817118A2 (es) |
| CA (1) | CA2696914A1 (es) |
| CL (1) | CL2008002786A1 (es) |
| CO (1) | CO6270207A2 (es) |
| EC (1) | ECSP10010039A (es) |
| GT (1) | GT201000062A (es) |
| MA (1) | MA31744B1 (es) |
| MX (1) | MX2010002970A (es) |
| PE (1) | PE20090706A1 (es) |
| RU (1) | RU2010115262A (es) |
| TN (1) | TN2010000097A1 (es) |
| TW (1) | TW200930416A (es) |
| WO (1) | WO2009039226A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017242544B2 (en) * | 2016-03-31 | 2022-11-24 | Midatech Ltd. | Cyclodextrin-panobinostat adduct |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7250514B1 (en) * | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR101139557B1 (ko) * | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
| JP2007501775A (ja) * | 2003-08-07 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 |
| PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| US20060128660A1 (en) * | 2004-12-10 | 2006-06-15 | Wisconsin Alumni Research Foundation | FK228 analogs and methods of making and using the same |
| US7604939B2 (en) * | 2005-03-01 | 2009-10-20 | The Regents Of The University Of Michigan | Methods of identifying active BRM expression-promoting HDAC inhibitors |
| AU2008204928B2 (en) * | 2007-01-10 | 2011-03-31 | Novartis Ag | Formulations of deacetylase inhibitors |
| EP2120900A2 (en) * | 2007-02-15 | 2009-11-25 | Novartis AG | Combination of lbh589 with other therapeutic agents for treating cancer |
-
2008
- 2008-09-17 CL CL2008002786A patent/CL2008002786A1/es unknown
- 2008-09-18 BR BRPI0817118A patent/BRPI0817118A2/pt not_active IP Right Cessation
- 2008-09-18 JP JP2010525936A patent/JP2010540445A/ja active Pending
- 2008-09-18 EP EP08832517A patent/EP2205222A1/en not_active Withdrawn
- 2008-09-18 RU RU2010115262/15A patent/RU2010115262A/ru unknown
- 2008-09-18 MX MX2010002970A patent/MX2010002970A/es not_active Application Discontinuation
- 2008-09-18 CA CA2696914A patent/CA2696914A1/en not_active Abandoned
- 2008-09-18 PE PE2008001634A patent/PE20090706A1/es not_active Application Discontinuation
- 2008-09-18 AR ARP080104055A patent/AR068822A1/es unknown
- 2008-09-18 US US12/676,755 patent/US20100331387A1/en not_active Abandoned
- 2008-09-18 WO PCT/US2008/076752 patent/WO2009039226A1/en not_active Ceased
- 2008-09-18 CN CN200880107798A patent/CN101801345A/zh active Pending
- 2008-09-18 KR KR1020107006075A patent/KR20100059887A/ko not_active Withdrawn
- 2008-09-18 AU AU2008302273A patent/AU2008302273A1/en not_active Abandoned
- 2008-09-19 TW TW097136190A patent/TW200930416A/zh unknown
-
2010
- 2010-02-25 TN TNP2010000097A patent/TN2010000097A1/fr unknown
- 2010-03-12 MA MA32691A patent/MA31744B1/fr unknown
- 2010-03-16 GT GT201000062A patent/GT201000062A/es unknown
- 2010-03-17 EC EC2010010039A patent/ECSP10010039A/es unknown
- 2010-03-25 CO CO10035474A patent/CO6270207A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP10010039A (es) | 2010-04-30 |
| GT201000062A (es) | 2012-03-30 |
| CA2696914A1 (en) | 2009-03-26 |
| RU2010115262A (ru) | 2011-10-27 |
| PE20090706A1 (es) | 2009-07-15 |
| TW200930416A (en) | 2009-07-16 |
| TN2010000097A1 (en) | 2011-09-26 |
| CO6270207A2 (es) | 2011-04-20 |
| US20100331387A1 (en) | 2010-12-30 |
| WO2009039226A1 (en) | 2009-03-26 |
| MX2010002970A (es) | 2010-04-01 |
| CN101801345A (zh) | 2010-08-11 |
| JP2010540445A (ja) | 2010-12-24 |
| AU2008302273A1 (en) | 2009-03-26 |
| KR20100059887A (ko) | 2010-06-04 |
| CL2008002786A1 (es) | 2009-05-15 |
| MA31744B1 (fr) | 2010-10-01 |
| BRPI0817118A2 (pt) | 2019-09-24 |
| EP2205222A1 (en) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000344A1 (en) | Combinations of therapeutic agents for treating cancer | |
| AR061298A1 (es) | Sales de n-hidroxi -3- [4- [ [ [2- (2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2- propenamida.composciones farmaceuticas. | |
| PE20090211A1 (es) | Inhibidores de las iap | |
| RU2012123372A (ru) | Гетероциклические модуляторы транспортеров атф-связывающей кассеты | |
| AR071959A1 (es) | Derivado de benceno o tiofeno y su uso como inhibidor de vap-1 | |
| TW200700083A (en) | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer | |
| CY1115710T1 (el) | Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης | |
| PE20081187A1 (es) | Combinaciones de inhibidores de ang2 y vegf | |
| NO20042361L (no) | Form av 3-[(2{4-(Heksyloksykarbonylamino-imino-metyl)-fenylami no]-metyl}-1- metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral | |
| PE20090244A1 (es) | Inhibidores de la proteina activadora de la 5-lipoxigenasa (flap) | |
| IL198979A (en) | Enzyme inhibitors diacylglycerol o-acetyltransferase type 1 | |
| MX2010004501A (es) | Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap). | |
| EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
| MA30511B1 (fr) | Polymorphes de n-hydroxy -3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2- propenamide | |
| MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
| CO6612204A2 (es) | Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina | |
| NO20090136L (no) | Fremgangsmate for fremstilling av salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-1ln-dol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid | |
| PE20061373A1 (es) | Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida | |
| AR064072A1 (es) | Combinacion para el tratamiento de una enfermedad proliferativa | |
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| ES2545076T3 (es) | Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma | |
| AR068822A1 (es) | Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso | |
| UA95289C2 (en) | Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide | |
| AR083322A1 (es) | Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo | |
| AR041475A1 (es) | Producto de acoplamiento entre la triptamina y un alfa-amino-acido, su proceso de preparacion asi como su aplicacion en el campo de la neurocosmetica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |